CompletedPhase 2NCT00036842
Arsenic Trioxide in Treating Men With Germ Cell Cancer
Studying Extragonadal germ cell tumor
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- SWOG Cancer Research Network
- Principal Investigator
- Tomasz M. Beer, MDOHSU Knight Cancer Institute
- Intervention
- arsenic trioxide(drug)
- Eligibility
- 16 years · MALE
- Timeline
- 2002 – 2007
Study locations (30)
- MBCCOP - Gulf Coast, Mobile, Alabama, United States
- CCOP - Western Regional, Arizona, Phoenix, Arizona, United States
- Veterans Affairs Medical Center - Phoenix (Carl T. Hayden), Phoenix, Arizona, United States
- Veterans Affairs Medical Center - Tucson, Tucson, Arizona, United States
- Arizona Cancer Center at University of Arizona Health Sciences Center, Tucson, Arizona, United States
- Arkansas Cancer Research Center at University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
- Veterans Affairs Medical Center - Little Rock, Little Rock, Arkansas, United States
- City of Hope Comprehensive Cancer Center, Duarte, California, United States
- USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, United States
- Veterans Affairs Medical Center - West Los Angeles, Los Angeles, California, United States
- Veterans Affairs Outpatient Clinic - Martinez, Martinez, California, United States
- CCOP - Bay Area Tumor Institute, Oakland, California, United States
- Chao Family Comprehensive Cancer Center at University of California Irvine Cancer Center, Orange, California, United States
- University of California Davis Cancer Center, Sacramento, California, United States
- CCOP - Santa Rosa Memorial Hospital, Santa Rosa, California, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00036842 on ClinicalTrials.govOther trials for Extragonadal germ cell tumor
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT06418789High-dose Chemotherapy as Second-line Drug Therapy for Relapsed Germ Cell TumorsN.N. Petrov National Medical Research Center of Oncology
- RECRUITINGPHASE3NCT03067181Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell TumorsChildren's Oncology Group
- ACTIVE NOT RECRUITINGPHASE3NCT02375204Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients with Relapsed or Refractory Germ Cell TumorsAlliance for Clinical Trials in Oncology